Vitamin D and Acute Optic Neuritis in Multiple Sclerosis
Using their multiple sclerosis (MS) database, the investigators aimed to identify clinical and demographic factors linked to severity and to prediction of recovery from acute optic neuritis (AON). Malik and colleagues enrolled 253 adults and 38 ...
Medscape - Mon, 21 Jul 2014 09:13

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
Top-line results from the first study in patients with optic neuritis will be announced in January. These optic neuritis data are highly anticipated by investors as substantial proof of concept for the entire remyelination thesis and as a signal for ... - Wed, 17 Dec 2014 06:15

MRIs May Be Able to Detect Patients at Risk for Developing Multiple Sclerosis
Participants who developed MS during the follow up period had demonstrated earlier symptoms of partial myelitis (4 patients), brain stem syndrome (1 patient), and optic neuritis (2 patients). No patient whose MRI demonstrated no signs of MS developed ...
HCPLive - Fri, 05 Dec 2014 13:33

Low Vitamin D is Linked to Severe Acute Optic Neuritis in Multiple Sclerosis
vitamin D metabolism For the approximately 15-20% of multiple sclerosis patients with acute optic neuritis (AON), lack of vitamin D may be partly responsible. A new study published in Neurology identified a link between vitamin D levels and AON severity.
Multiple Sclerosis News Today - Thu, 24 Jul 2014 04:45

817 Miles and Counting: Shawn Hikes for MS Awareness
Within a few days I was diagnosed with optic neuritis and MS. The doctor left a message to give me the news. I ate well, was a gym rat, ran at least three times a week, so the diagnosis came as a shock, as it does for many of us. DL: Why did you decide ...
Everyday Health - Wed, 10 Dec 2014 01:38

The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley
Morgan Stanley sees about $60 per share of value in BIIB037, an anti Aβ-human monoclonal antibody that Biogen is testing as a treatment for Alzheimer's Disease and acute optic neuritis (AON). Biogen is also expecting data in 2015 on its drug Tysabri, ...
Benzinga - Thu, 11 Dec 2014 10:00

International Breast Cancer Study Group, Breast International Group and Merck ...
... with KEYTRUDA: exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures arising in a patient with inflammatory foci in brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic neuritis, and ... - Wed, 10 Dec 2014 05:41

Latest Updates on Biogen Idec Inc. (NASDAQ:BIIB)
The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 ...
Inside Trade - Wed, 03 Dec 2014 06:56

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014